Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone

Acknowledgements Professor Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Jaco Vooriham is acknowledged for his contribution to protocol development. We would also like to acknowledge Ms. Shilpa Suresh (MSc) of the Observational and Pragmatic Research Institute (OPRI), Singapore, for editorial and formatting assistance which supported the development of this publication.Peer reviewedPublisher PD